Cargando…

Trial Refresh: A Case for an Adaptive Platform Trial for Pulmonary Exacerbations of Cystic Fibrosis

Cystic fibrosis is a genetic disease typically characterized by progressive lung damage and premature mortality. Pulmonary exacerbations, or flare-ups of the lung disease, often require hospitalization for intensive treatment. Approximately 25% of patients with cystic fibrosis do not recover their b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schultz, Andre, Marsh, Julie A., Saville, Benjamin R., Norman, Richard, Middleton, Peter G., Greville, Hugh W., Bellgard, Matthew I., Berry, Scott M., Snelling, Tom
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447696/ https://www.ncbi.nlm.nih.gov/pubmed/30983998 http://dx.doi.org/10.3389/fphar.2019.00301

Ejemplares similares

BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis
por: Schultz, Andre, et al.
Publicado: (2023)

Variation in treatment preferences of pulmonary exacerbations among Australian and New Zealand cystic fibrosis physicians
por: Currie, Grace, et al.
Publicado: (2021)

A refresh of the top 10 research priorities in cystic fibrosis
por: Rowbotham, Nicola Jane, et al.
Publicado: (2023)

Designing Clinical Trials for Anti-Inflammatory Therapies in Cystic Fibrosis
por: Perrem, Lucy, et al.
Publicado: (2020)

Efficacy and Safety of Triple Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Patients With Cystic Fibrosis: A Meta-Analysis of Randomized Controlled Trials
por: Wang, Yizi, et al.
Publicado: (2022)

Evaluating the efficacy of inhaled amikacin as an adjunct to intravenous combination therapy (ceftazidime and amikacin) in pediatric cystic fibrosis pulmonary exacerbation
por: Rakhshan, Amin, et al.
Publicado: (2023)

Protocol for establishing a core outcome set for evaluation in studies of pulmonary exacerbations in people with cystic fibrosis
por: McLeod, Charlie, et al.
Publicado: (2022)

Discrete choice experiment to evaluate preferences of patients with cystic fibrosis among alternative treatment-related health outcomes: a protocol
por: McLeod, Charlie, et al.
Publicado: (2019)

Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study
por: Fila, Libor, et al.
Publicado: (2023)

Inhaled hypertonic saline in adults hospitalised for exacerbation of cystic fibrosis lung disease: a retrospective study
por: Pezzulo, Alejandro A, et al.
Publicado: (2012)

A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C
por: Ramsay, Jessica, et al.
Publicado: (2020)

Animal Models in the Pathophysiology of Cystic Fibrosis
por: Semaniakou, Anna, et al.
Publicado: (2019)

The Resolution Approach to Cystic Fibrosis Inflammation
por: Recchiuti, Antonio, et al.
Publicado: (2020)

Enhancing Cystic Fibrosis Immune Regulation
por: van Heeckeren, Anna M., et al.
Publicado: (2021)

Endobronchial Therapy With Gentamicin and Dexamethasone After Airway Clearance by Bronchoscopy in Exacerbation of Non-Cystic Fibrosis Bronchiectasis: A Real-World Observational Study
por: Li, Qiuhong, et al.
Publicado: (2021)

Refreshing memories
por: Lisman, John E
Publicado: (2014)

Factors Contributing to Exacerbating Vulnerabilities in Global Clinical Trials
por: da Silva, Ricardo E., et al.
Publicado: (2018)

CFTR and Ca(2+) Signaling in Cystic Fibrosis
por: Antigny, Fabrice, et al.
Publicado: (2011)

Strategies to circumvent the CFTR defect in cystic fibrosis
por: Becq, Frédéric, et al.
Publicado: (2013)

Personalized or Precision Medicine? The Example of Cystic Fibrosis
por: Marson, Fernando A. L., et al.
Publicado: (2017)

Editorial: Emerging Therapeutic Approaches for Cystic Fibrosis
por: Lopes-Pacheco, Miquéias, et al.
Publicado: (2019)

Cystic Fibrosis Lung Disease in the Aging Population
por: Künzi, Lisa, et al.
Publicado: (2021)

Gene therapy for cystic fibrosis: Challenges and prospects
por: Sui, Hongshu, et al.
Publicado: (2022)

Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials
por: VanDevanter, Donald R., et al.
Publicado: (2021)

Genetic Influences on Cystic Fibrosis Lung Disease Severity
por: Weiler, Colleen A., et al.
Publicado: (2013)

TMEM16A in Cystic Fibrosis: Activating or Inhibiting?
por: Kunzelmann, Karl, et al.
Publicado: (2019)

Antimicrobial Treatment of Staphylococcus aureus in Patients With Cystic Fibrosis
por: Esposito, Susanna, et al.
Publicado: (2019)

Emerging microRNA Therapeutic Approaches for Cystic Fibrosis
por: Bardin, Pauline, et al.
Publicado: (2018)

Mitochondrial Stress Responses and “Mito-Inflammation” in Cystic Fibrosis
por: Patergnani, Simone, et al.
Publicado: (2020)

Update on Calcium Signaling in Cystic Fibrosis Lung Disease
por: Rimessi, Alessandro, et al.
Publicado: (2021)

On the Corner of Models and Cure: Gene Editing in Cystic Fibrosis
por: Ensinck, Marjolein, et al.
Publicado: (2021)

Novel electronic refreshers for cardiopulmonary resuscitation: a randomized controlled trial
por: Magura, Stephen, et al.
Publicado: (2012)

REFRESHER COURSE FOR PRACTITIONERS
Publicado: (1956)

Time: the refreshing river
por: Needham, Joseph
Publicado: (1944)

Molecular Chaperones as Targets to Circumvent the CFTR Defect in Cystic Fibrosis
por: Chanoux, Rebecca A., et al.
Publicado: (2012)

PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis
por: Noel, Sabrina, et al.
Publicado: (2012)

CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis
por: Lopes-Pacheco, Miquéias
Publicado: (2016)

Treatment of Cystic Fibrosis: From Gene- to Cell-Based Therapies
por: Allan, Katelin M., et al.
Publicado: (2021)

The effect of CFTR modulators on structural lung disease in cystic fibrosis
por: Mok, L. Clara, et al.
Publicado: (2023)

Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial
por: Devereux, Graham, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_90s3fgvovufvlrmvorcj0is38d